Table SI. Previous (before entry in the cohort) and current systemic therapy, by sex

Therapeutic characteristics	Males ($n = 1,680$)	Females ($n = 1,201$)	Total ($n = 2,881$)	p-value
Number of previous classical treatments, n (%)				0.0031
0	744 (44)	568 (47)	1,312 (46)	
1	503 (30)	380 (32)	883 (31)	
2	305 (18)	199 (17)	504 (17)	
3 or more	128 (8)	54 (4)	182 (6)	
Number of previous modern treatments, n (%)				0.1014
0	1,482 (88)	1,086 (90)	2,568 (89)	
1	143 (9)	81 (7)	224 (8)	
2	31 (2)	25 (2)	56 (2)	
3 or more	24 (1)	9 (1)	33 (1)	
Previous phototherapy, n (%)				0.0014
Yes	601 (36)	500 (42)	1,101 (38)	
Treatment order: 1,2,3 or more, n (%)[a]				0.2162
1	1,549 (48)	1,117 (46)	2,666 (47)	
2	749 (23)	552 (23)	1,301 (23)	
3 or more	949 (29)	762 (31)	1,711 (30)	
First treatment, n (%)				<0.0001
Etanercept	253 (15)	186 (15)	439 (15)	
Infliximab	48 (3)	19 (2)	67 (2)	
Adalimumab	230 (14)	129 (11)	359 (12)	
Ustekinumab	208 (12)	124 (10)	332 (12)	
Acitretin	256 (15)	128 (11)	384 (13)	
Cyclosporine	173 (10)	160 (13)	333 (12)	
Methotrexate	389 (23)	346 (29)	735 (26)	
Secukinumab	65 (4)	43 (4)	108 (4)	
Apremilast	34 (2)	52 (4)	86 (3)	
Ixekizumab	24 (1)	14 (1)	38 (1)	
All treatment cycles (current and past), n (%)				<0.0001
Etanercept	485 (15)	376 (15)	861 (15)	
Infliximab	82 (3)	46 (2)	128 (2)	
Adalimumab	524 (16)	332 (14)	856 (15)	
Ustekinumab	484 (15)	365 (15)	849 (15)	
Acitretin	431 (13)	207 (9)	638 (11)	
Cyclosporine	274 (8)	248 (10)	522 (9)	
Methotrexate	691 (21)	603 (25)	1,294 (23)	
Secukinumab	147 (5)	122 (5)	269 (5)	
Apremilast	62 (2)	96 (4)	158 (3)	
Ixekizumab	67 (2)	36 (1)	103 (2)	
Current modern therapy (biologic or small molecules), n (%)				0.0300
Yes	862 (51)	567 (47)	1,429 (50)	

[a]1: First treatment. 2: Second treatment. 3 or more: Third or subsequent treatments.
Shaded areas correspond to variables with a p-value <0.05.